DR. SONAL MANOHAR
Assistant Professor, Biological Sciences
Specialization: Cancer biology, Cell biology,
Cell Signaling
B.Sc.- Life Sciences, M.Sc.- Life Sciences (Biotechnology),
Ph.D.- Applied Biology
Areas of Specialization
Cancer Biology
Academic/Research Experience
Dr. Sonal has been working with Sunandan Divatia School of Science
from March 2019 and has over 14 years of research experience, which includes
over 8 years of industrial experience in anticancer drug discovery. She
obtained her Ph.D. in Applied Biology from Piramal Life Sciences Ltd., Mumbai,
India, where she delineated molecular pharmacology of cyclin-dependent kinase
(CDK) inhibitory drugs in colorectal cancer cells. Further, she worked as a
postdoctoral researcher at IIT Bombay, Mumbai, India wherein she developed a
flow cytometry-based assay for studying cell-signaling events at single cell
level in adherent cancer cell lines. This assay enables rapid, high-throughput
analysis for understanding of cell-to-cell heterogeneity that is inherent in
tumor populations.
Areas of Research
Her current active research areas focus on assessment of efficacy
and molecular pharmacology of targeted agents against common cancers in women
viz. breast cancer and cervical cancer.
Ph.D. Students
1. Ms. Anusree Nair
Title
of the project –
Investigating the Efficacy and Mechanism of Action of
ONC201 in Combination with Standard Chemotherapeutic Agents in Human Cancer
Cells.
2. Ms. Sneha Pathak (CSIR- NET JRF)
Title of the project –
To
investigate the efficacy and mechanism of action of ONC201 (TRAIL inducer and
dual Akt/ERK inhibitor) in cervical carcinoma cell lines
Selected Publications
Papers
- Manohar
SM*, Shah P, Nair A (2021). Flow Cytometry: Principles, Applications and
Recent Advances. Bioanalysis https://doi.org/10.4155/bio-2020-0267. Impact factor 2.673.
- Manohar
SM* and Joshi KS (2021). Role of Cyclin Dependent Kinase inhibitors as
Potential Therapeutic Agents against Human Colorectal Carcinoma Cells. In
communication.
- Manohar
SM* (2021). Cell Cycle Aberrations in Colorectal Cancer: Perspectives for
Targeted Therapies. In communication.
- Manohar
S, Shah P, Biswas S, Mukadam A, Joshi M, Viswanathan G. Combining
fluorescent cell barcoding and flow cytometry-based phospho-ERK1/2
detection at short time-scales in adherent cells. Cytometry A 2019; 95(2):
192-200. Impact factor 3.26. (Editor’s pick as a featured article)
- Aware
V, Gaikwad N, Chavan S, Manohar S, Bose J, Khanna S, et al.
Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R
inhibitor. European Journal of Medicinal Chemistry 2015; 92: 246-256.
Impact factor 4.816.
- Godse
P, Kumar P, Yewalkar N, Deore V, Lohar M, Mundada R, Padgaonkar A, Manohar
S, Joshi A, et al. Discovery of P3971 an orally efficacious novel
anticancer agent targeting HIF-1alpha and STAT-3 pathways. Anticancer
Agents in Medicinal Chemistry 2013; 13: 1460. Impact factor 2.556.
- Rathos
MJ, Khanwalkar H, Joshi K, Manohar SM, Joshi KS. Potentiation of in vitro
and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase
inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer
2013; 13:29. Impact factor 3.288.
- Manohar
SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS. Cyclin-dependent
kinase inhibitor, P276-00, inhibits HIF-1alpha and indues G2/M arrest
under hypoxia in prostate cancer cells. Prostate Cancer and Prostatic
Diseases 2012; 15:15. Impact factor 3.8.
- Shirsath
NP, Manohar SM, Joshi KS. P276-00, a cyclin-dependent kinase inhibitor,
modulates cell cycle and induces apoptosis in vitro and in vivo in mantle
cell lymphoma cell lines. Molecular Cancer 2012; 11:77. Impact factor
7.776.
- Rathos
MJ, Joshi K, Khanwalkar H, Manohar SM, Joshi KS. Molecular evidence for
increased antitumor activity of gemcitabine in combination with a
cyclin-dependent kinase inhibitor P276-00 in pancreatic cancers. Journal
of Translational Medicine 2012; 10: 161. Impact factor 3.786.
- Patil
RC, Manohar SM, Katchi VI, Rao AJ, Moghe A. Ethanolic stem extract of
Excoecaria agallocha induces G1 arrest or apoptosis in human lung cancer
cells depending on their p53 status. Taiwania: International Journal of
Life Sciences, 2012; 57: 89. Impact factor 0.421.
- Manohar
SM, Padgaonkar AA, Jalota-Badhwar A, et al. A novel inhibitor of
HIF-1alpha P3155 also modulates PI3K pathway and inhibits growth of
prostate cancer cells. BMC Cancer 2011; 11:238. Impact factor 3.288.
- Manohar
SM, Rathos MJ, Sonawane V, Rao S, Joshi KS. Cyclin dependent kinase
inhibitor P276-00 induces apoptosis in multiple myeloma cells by
inhibition of Cdk9 and RNA polymerase II-dependent transcription. Leukemia
Research 2011; 35: 821. Impact factor 2.319.
- Wagh
V, Chile S, Manohar SM, Sharma S, Joshi KS. NPB001-056 specifically
inhibits BcrAbl expressing cells by inducing apoptosis and inhibits kinase
activity of Bcr-Abl and with T315I mutation. Frontiers in Biosciences June
2011; E3 1273. Impact factor 2.349.
- Yewalkar
N, Deore V, Padgaonkar A, Manohar SM, Sahu B, Kumar P, et al. Development
of novel inhibitors targeting HIF-1alpha towards anticancer drug
discovery. Bio-organic and Medicinal Chemistry Letters 2010; 20: 6426.
Impact factor 2.42.
Book Chapter
- Manohar
SM* (2020). Insights into the Molecular Drivers of Prostate Cancer. In: HS
Watanabe (Ed.) Horizons in Cancer Research (Vol. 76). Nova Science
Publishers, New York, USA.
* Corresponding author
Patents
- Substituted
pyrimidine compounds and uses thereof. Publication number-WO 2013175415
A1. Publication date- November 28, 2013.
- A
pharmaceutical combination for the treatment of breast cancer. Publication
number - WO 2012069972 A1. Publication date- May 31, 2012.
- Oxadiazole
compounds, their preparation and use. Publication number - WO2011104680
A1. Publication date - September 1, 2011.
For complete
publications list go to:
https://scholar.google.co.in/citations?user=NI82jhMAAAAJ&hl=en
Citations: 302 h-index: 11 i10-index:
12
Official Email Id
Sonal.Manohar@nmims.edu
Official Phone No.
022-4235-5952